New Studies Heat Up Controversial Statin Debate

New studies are adding fuel to the long-running debate over statins, a group of cholesterol-lowering drugs that generate about $26 billion in annual sales, the Los Angeles Times reports.

A study in the medical journal Cancer reports that statins can help men who have had surgery for prostate cancer prevent a recurrence of the disease.

But a second study and a new analysis published in the Archives of Internal Medicine are calling into question the drugs’ ability to lower death rates for people without heart problems. Scientists agree that statins reduce the risk of heart attack in people with heart disease, but experts continue to argue over whether the drugs can prevent heart attacks in healthy populations, Time Magazine reports.

The new analysis examines 11 previous studies which found that statins did not significantly lower death rates for 65,000 patients with risk factors for a heart attack but without cardiovascular disease. The lead author of the review, Dr. Kausik Ray, formerly of St. George’s, University of London, is now cautioning against giving statins, which can cause serious side effects, to low-risk patients.

The journal also published a new study that claims a controversial clinical trial, which found AstraZeneca’s statin Crestor prevented hearts attack in healthy people, may have been biased. According to the report, nine of 14 researchers who conducted the study had some sort of financial ties to the drugmaker, which could have influenced the trial.

“The possibility that bias entered the study is particularly concerning because of the strong commercial interest in the study,” lead researcher Michel de Lorgeril wrote in the report.

Print Print  

Like what we're doing? We'd appreciate your support.

Leave a comment